Table 4

Disease activity analyses after the first and second dose of the Sinovac-CoronaVac vaccine in patients with rheumatoid arthritis

		After first dose (D28)	P value	After second dose (D69)	P value	At any moment	P value
ΔDAS28-CRP ≥1.2 or ΔDAS28-CRP ≥0.6 + DAS28-CRP >3.2	MTX-hold (n=60)	7 (11.7)	0.576	12 (20)	0.188	22 (36.7)	0.094
ΔDAS28-CRP ≥1.2 or ΔDAS28-CRP ≥0.6 + DAS28-CRP >3.2	MTX-maintain (n=69)	6 (8.7)	0.576	8 (11.6)	0.188	16 (23.2)	0.094
CDAI >10	MTX-hold (n=60)	13 (21.7)	0.122	19 (31.7)	0.011	23 (38.3)	0.024
CDAI >10	MTX-maintain (n=69)	8 (11.6)	0.122	9 (13)	0.011	14 (20.3)	0.024
Patient impression of disease flare	MTX-hold (n=60)	6 (10)	0.577	8 (13.3)	0.044	14 (23.3)	0.022
Patient impression of disease flare	MTX-maintain (n=69)	5 (7.2)	0.577	2 (2.3)	0.044	6 (8.7)	0.022

For safety analyses, all patients who adhered to the protocol were included.
Results are expressed in n (%) and compared with χ² or Fisher’s exact test, as appropriate, as two-sided analyses.
CDAI, Clinical Disease Activity Index; D28, day 28; D69, day 69; DAS28-CRP, Disease Activity Score with 28 joints and C reactive protein; MTX, methotrexate; ΔDAS28-CRP, variation of DAS28-CRP score.